Row 11749

Row ID: 11749 | Dataset Entry | Axioma AXP Content Repository

Content Data

This page contains data entry 11749 from the Axioma AXP content repository. The structured data below represents the complete record for this entry.

"Dudum said the drugs will be made at an FDA-licensed facility that he described vaguely as “one of the largest generics manufacturers” in the country. He evaluated more than 100 potential partners before striking a deal with a supplier that offered enough assurances on volume to give him confidence that the company will be able to meet demand."

"Dudum also plans to integrate the real, name-brand drugs when adequate supply is available."

https://www.bloomberg.com/news/articles/2024-05-20/hims-debuts-199-weight-loss-shots-undercutting-wegovy-ozempic?utm_source=website&utm_medium=share&utm_campaign=copy

I am cautious of a flash in the pan type reaction here - but from the CEO this infers that they may have access to these drugs, albeit less profitably, once the FDA declared shortage is over.

Interesting you cite the differences in form. Is the different form unrestricted by patent, or are they using the different form because the actual manner Wegovy constructs the medicine is too complex or expensive likely?

FieldValue
text "Dudum said the drugs will be made at an FDA-licensed facility that he described vaguely as “one of the largest generics manufacturers” in the country. He evaluated more than 100 potential partners before striking a deal with a supplier that offered enough assurances on volume to give him confidence that the company will be able to meet demand." "Dudum also plans to integrate the real, name-brand drugs when adequate supply is available." https://www.bloomberg.com/news/articles/2024-05-20/hims-…
label r/health
dataType comment
communityName r/Health
datetime 2024-05-20
username_encoded Z0FBQUFBQm5Lakw2Z211aEktZjdsZHJjM0ZOWFFtR19XdFFjZnRuN05WOEFqaTRuQzBDRWRFb3BCeDBjUTZVSGVOTEpydkxBNkZScXJNVUotbzBhajN0Z096YUlDT29sNXc9PQ==
url_encoded Z0FBQUFBQm5Lak9KRmw5ZXZsNEhnbHN6WTJsenM3U29CWlNUT2cwVXdfU3VRZi1hXzZvbHg3ZG9rVm9nY2xvX0ZJeEhSdERUd2J4TFVrVUZ6YzJsZkhvODJvcndBaC1aUVBJZnlPTGNwUTBHZGVSRnFxZEdPU2ZwMG4wZGJScUlQcVBDOTZ5RmxudGJKOUFtMHdQSHJrczZicGdzc0VYRE9tRlJWUXVGVm5mbV91aDFlcU5kQ2VFSm96bEdpM3RWVURIMWlyd0doUnk2OGdGSDA1LTROcWlWVHU1djdZVlM4UT09

Raw Record

{
  "text": "\"Dudum said the drugs will be made at an FDA-licensed facility that he described vaguely as “one of the largest generics manufacturers” in the country. He evaluated more than 100 potential partners before striking a deal with a supplier that offered enough assurances on volume to give him confidence that the company will be able to meet demand.\"\n\n\"Dudum also plans to integrate the real, name-brand drugs when adequate supply is available.\"\n\nhttps://www.bloomberg.com/news/articles/2024-05-20/hims-debuts-199-weight-loss-shots-undercutting-wegovy-ozempic?utm_source=website&utm_medium=share&utm_campaign=copy\n\nI am cautious of a flash in the pan type reaction here - but from the CEO this infers that they may have access to these drugs, albeit less profitably, once the FDA declared shortage is over.\n\nInteresting you cite the differences in form. Is the different form unrestricted by patent, or are they using the different form because the actual manner Wegovy constructs the medicine is too complex or expensive likely?",
  "label": "r/health",
  "dataType": "comment",
  "communityName": "r/Health",
  "datetime": "2024-05-20",
  "username_encoded": "Z0FBQUFBQm5Lakw2Z211aEktZjdsZHJjM0ZOWFFtR19XdFFjZnRuN05WOEFqaTRuQzBDRWRFb3BCeDBjUTZVSGVOTEpydkxBNkZScXJNVUotbzBhajN0Z096YUlDT29sNXc9PQ==",
  "url_encoded": "Z0FBQUFBQm5Lak9KRmw5ZXZsNEhnbHN6WTJsenM3U29CWlNUT2cwVXdfU3VRZi1hXzZvbHg3ZG9rVm9nY2xvX0ZJeEhSdERUd2J4TFVrVUZ6YzJsZkhvODJvcndBaC1aUVBJZnlPTGNwUTBHZGVSRnFxZEdPU2ZwMG4wZGJScUlQcVBDOTZ5RmxudGJKOUFtMHdQSHJrczZicGdzc0VYRE9tRlJWUXVGVm5mbV91aDFlcU5kQ2VFSm96bEdpM3RWVURIMWlyd0doUnk2OGdGSDA1LTROcWlWVHU1djdZVlM4UT09"
}
Explore Dataset Explore Row

Entry Information